Advertisement
UK markets close in 2 hours 51 minutes
  • FTSE 100

    8,116.86
    +38.00 (+0.47%)
     
  • FTSE 250

    19,791.49
    +189.51 (+0.97%)
     
  • AIM

    754.70
    +1.58 (+0.21%)
     
  • GBP/EUR

    1.1669
    +0.0012 (+0.11%)
     
  • GBP/USD

    1.2520
    +0.0009 (+0.07%)
     
  • Bitcoin GBP

    51,415.57
    +357.50 (+0.70%)
     
  • CMC Crypto 200

    1,388.85
    -7.68 (-0.55%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • CRUDE OIL

    84.27
    +0.70 (+0.84%)
     
  • GOLD FUTURES

    2,355.60
    +13.10 (+0.56%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,054.51
    +137.23 (+0.77%)
     
  • CAC 40

    8,052.55
    +35.90 (+0.45%)
     

Boston Scientific’s Electrophysiology and Neuromodulation Areas

Boston Scientific’s Electrophysiology and Neuromodulation Areas

Worldwide revenues of Boston Scientific’s (BSX) electrophysiology business, which includes less invasive medical technologies for rate and rhythm disorders of the heart, grew 20% from $64 million in Q1 2017 to $75 million in Q1 2018. Electrophysiology revenues from the United States increased from $32 million in Q17 to $35 million in 1Q18.